… Therefore, treatment of the cytokine storm has become an … -6 (IL-6) plays an important role
in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it …

… to the use of the IL-6 receptor inhibitor tocilizumab for the management of CRS. Tocilizumab
is a … monoclonal antibody against both the soluble and membrane-bound IL-6 receptor. …

… The goal of this study was to determine if tocilizumab benefits patients hospitalized with …
received tocilizumab for evolving CRS. Tocilizumab-treated patients with severe disease had …

… IL‐6R and inhibits IL‐6‐mediated signaling through these receptors. Herein, we … tocilizumab
for treatment of severe or life‐threatening CAR T cell‐induced cytokine release syndrome…

… and safety of tocilizumab (TCZ) and to investigate the factors related to the progress and
mortality of patients with a secondary cytokine release syndrome caused by SARS-CoV-2. …

… Citation64,Citation65 Other potential therapies include ruxolitinib, a Janus kinase inhibitor,
anakinra, an IL-1 receptor antagonist, and Cytosorb cartridge columns; all of these have been …

… spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal … IL-6
receptor antagonist that is commonly used to treat CRS secondary to chimeric antigen receptor …

… Background: Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine
release syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) …

… tocilizumab (Actemra®), an interleukin-6 receptor antagonist, for the treatment of chimeric
antigen receptor (… The authors report on the experience with tocilizumab for the management of …

… Cytokine release syndrome (CRS), resulting from rapid immune activation induced by CAR-…
high levels of cytokines including IL-6. Tocilizumab, an anti-IL-6 receptor antagonist, is the …